Novogene Co Ltd
SSE:688315
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Biogaia AB
STO:BIOG B
|
SE |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (2.5), the stock would be worth ¥15.68 (9% upside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 2.3 | ¥14.4 |
0%
|
| 3-Year Average | 2.5 | ¥15.68 |
+9%
|
| 5-Year Average | 4.3 | ¥27.55 |
+91%
|
| Industry Average | 3.7 | ¥23.4 |
+63%
|
| Country Average | 2.4 | ¥15.54 |
+8%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Novogene Co Ltd
SSE:688315
|
5.8B CNY | 2.3 | 29.5 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
936.1B USD | 129.1 | 3 881 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
174.7B USD | 3.3 | 25.3 | |
| US |
|
Danaher Corp
NYSE:DHR
|
126.7B USD | 2.4 | 34.3 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 6.8 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
329.9B CNY | 4.2 | 17.3 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
33.1B CHF | 3.8 | -118.7 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.5B USD | 4.5 | 24.3 | |
| US |
|
Waters Corp
NYSE:WAT
|
29.5B USD | 11.1 | 44.4 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27B USD | 4.1 | 19.6 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
25.7B USD | -1 068.2 | 29 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.4 |
| 70th Percentile | 3.9 |
| Max | 1 172 445.9 |
Other Multiples
Novogene Co Ltd
Glance View
Novogene Co., Ltd. engages in the provision of genomic services and solutions. The company is headquartered in Beijing, Beijing and currently employs 2,284 full-time employees. The company went IPO on 2021-04-13. The firm mainly relies on high-throughput sequencing technology and bioinformatics analysis technology to establish gene sequencing platforms. Combined with multi-omics research technology, the Company provides multi-level scientific and research technical services and solutions for life science basic research, medical and clinical application research. At the same time, based on the technology accumulation in gene sequencing and its application fields, the Company independently develops genetic testing medical equipment. The firm's services mainly include life science basic scientific research services, medical research and technical services, and database-building sequencing platform services. Its other services and products include gene mutation detection kits, coronavirus disease nucleic acid test service and DA8600 sequencers. The firm conducts its businesses in domestic and overseas markets.
